Core Viewpoint - The Second Global Ophthalmology Conference 2026 will be held on June 11, 2026, in Beijing, focusing on the integration of medicine and engineering, technological innovation, and clinical value in the ophthalmology industry [1]. Event Overview - The conference will cover various fields including ophthalmic imaging, refractive and myopia treatment, innovative therapies, surgical techniques, and preclinical validation [1]. - The event will also open applications for the "2026 Global Ophthalmology Annual Awards" and invite teams to co-author the "Global Ophthalmology Innovation White Paper" [2]. Conference Highlights - The conference will feature the release of the "2026 Global Ophthalmology Innovation White Paper" and the awarding of the "Ophthalmology Innovation Series Awards" to establish industry benchmarks [7]. - There will be premium exhibition spaces for sponsors to engage with high-quality decision-makers, product demonstrations, and collaboration opportunities [7]. - An "Innovation Demo Hour" will allow selected innovative teams to present their projects in 5-10 minute high-density pitches, addressing investment and collaboration needs [14]. Thematic Focus Areas - **Next-Generation Ophthalmic Imaging and AI**: This section will explore the integration of imaging and algorithms, focusing on academic advancements and practical applications [11]. - **Refractive and Myopia**: This segment will address the largest commercial segment in China's ophthalmology industry, discussing refined surgical developments and comprehensive strategies for myopia prevention [13]. - **Surgical Innovations**: This part will showcase the next-generation technologies in ophthalmic surgery, including robotics and real-time imaging [13]. - **Device Development and Preclinical Validation**: This section will present the system of "industrial service chains" to assist R&D and innovation companies in resource matching [13]. Participant Demographics - The conference will attract a diverse audience, including academic teams with recent research outcomes, engineering teams with prototype products, and early-stage innovative companies [16].

Core Viewpoint - The Second Global Ophthalmology Conference 2026 will be held on March 19, 2026, in Beijing, focusing on the integration of medicine and engineering, technological innovation, and clinical value in the ophthalmology industry [1]. Event Overview - The conference will cover various trends in ophthalmology, including imaging, refractive and myopia treatment, innovative therapies, surgical techniques, and preclinical validation [1]. - The event will also open applications for the "2026 Global Ophthalmology Annual Awards" and invite teams to co-author the "Global Ophthalmology Innovation White Paper" [2]. Conference Highlights - The conference will feature the release of the "2026 Global Ophthalmology Innovation White Paper" and the awarding of the "Ophthalmology Innovation Series Awards" to establish industry benchmarks [7]. - There will be premium exhibition spaces for sponsors to engage with high-quality decision-makers, product demonstrations, and collaboration opportunities [7]. - An "Innovation Demo Hour" will allow selected innovative teams to present their projects in 5-10 minute high-density pitches, addressing investment and collaboration needs [14]. Thematic Focus Areas - **Next-Generation Ophthalmic Imaging and AI**: This section will explore the integration of imaging and algorithms, focusing on academic advancements and practical applications [11]. - **Refractive, Vision Care, and Glaucoma**: This segment will address the commercial aspects of refractive surgery and myopia prevention strategies, including optical, pharmaceutical, and behavioral interventions [13]. - **Surgical Innovations**: The conference will showcase next-generation surgical technologies, including robotics and real-time imaging for enhanced precision [13]. - **Device Development and Preclinical Validation**: This area will present the system of "industrial service chains" to assist research and innovation enterprises in resource matching [13]. Participation and Collaboration - The conference aims to attract a diverse audience, including academic teams with recent research outcomes, engineering teams with prototype products, and early-stage innovative companies [16]. - Collaboration opportunities are available for those interested in participating in the conference, with contact details provided for the organizing team [17].

Core Viewpoint - The company reported a significant decline in revenue and an increase in R&D expenses, indicating challenges in sales and a focus on innovation [1][2] Group 1: Financial Performance - The company achieved revenue of RMB 49.451 million for the six months ending June 30, 2025, representing a year-on-year decrease of 80.54% [1] - R&D expenses amounted to RMB 105 million, reflecting a year-on-year increase of 58.75% [1] - The net loss for the period was RMB 270 million, with a basic loss per share of RMB 0.21 [1] Group 2: Revenue Breakdown - Revenue included sales from drugs (Apatinib and Pralsetinib) totaling RMB 20 million, licensing fee income of RMB 17.9 million, and royalties from Suglitinib of RMB 11.3 million [1] - Sales of Pralsetinib saw a significant decline, primarily due to price adjustments and one-time channel compensation in preparation for negotiations for inclusion in the National Medical Insurance Catalog [1] - The company anticipates that if Pralsetinib is included in the National Medical Insurance Catalog, the sales growth benefits in 2026 and beyond will offset the short-term negative impact on revenue [1] Group 3: Strategic Developments - The company accelerated its global expansion strategy and advanced its differentiated pipeline through strategic partnerships [2] - Significant achievements were made in regulatory approvals, clinical progress, and strategic collaborations, reinforcing the company's position in the field of innovative therapies [2] - A major external licensing agreement was signed with Istituto Gentili in July 2025, with expected licensing fee income in the second half of 2025 [1]